ArticleBMJ (Clinical research ed.)2023
Health and nutrition claims for infant formula: international cross sectional survey.
Article in BMJ (Clinical research ed.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Associations Between Carotenoid Status, Visual Outcomes and Cognitive Metrics in Children: A Scoping Review.Nutrients · 2026Article
- Operation Stork Speed represents an opportunity to reform infant formula clinical trials.Nature food · 2026Article
- Generalized structural equation modeling of intimate partner violence among married women in East Africa using population-based data.Scientific reports · 2026Article
- Starch-based thickening in infant formula:Frontiers in nutrition · 2026Article
- Profits Before Health? New Zealand Government Rejection of Stricter Infant Formula Marketing Standards and the Lobbying Behind It.Maternal & child nutrition · 2025Article
- Food Allergy in Children in China.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Review
- A Content Analysis of Digital Marketing Strategies of Formula Companies and Influencers to Promote Commercial Milk Formula in Hong Kong.Maternal & child nutrition · 2025Article
- Digital Marketing Claims and Their Association With the Perceptions of Parents of Children Under 2 Years Old of Commercial Milk Formulas in Mexico.Maternal & child nutrition · 2025Article
- Commercial influences on infant and young child feeding.Future healthcare journal · 2025Article
- Formula Labelling in the United Kingdom: Manufacturers' Compliance With the Code, UK Law and Guidance Notes.Maternal & child nutrition · 2025Article
- Research on commercial milk formulas for young children: A scoping review.Maternal & child nutrition · 2024Article
- A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation.Signal transduction and targeted therapy · 2024Review
- Article
- [Digital marketing of commercial infant formula in Argentina: a digital ethnographic study].Salud colectiva · 2024Article
- High rates of International Code violations: a cross-sectional study in a region of Canada with low breastfeeding rates.BMC research notes · 2024Article
- A long-acting prolactin to combat lactation insufficiency.bioRxiv : the preprint server for biology · 2023Article
- Dietary Implications of Polyunsaturated Fatty Acids during Pregnancy and in Neonates.Life (Basel, Switzerland) · 2023Review
- Iron and DHA in Infant Formula Purchased in the US Fails to Meet European Nutrition Requirements.Nutrients · 2023Article
- Law matters - assessment of country-level code implementation and sales of breastmilk substitutes in South Asia.Frontiers in public health · 2023Article
- Marketing and child feeding.Jornal de pediatriaReview
Corrections and comments
- Commented on by
Authors and funding
38 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo review available health and nutrition claims for infant formula products in multiple countries and to evaluate the validity of the evidence used for substantiation of claims.
designInternational cross sectional survey.
settingPublic facing and healthcare professional facing company owned or company managed formula industry websites providing information about products marketed for healthy infants delivered at full term in 15 countries: Australia, Canada, Germany, India, Italy, Japan, Nigeria, Norway, Pakistan, Russia, Saudi Arabia, South Africa, Spain, the United Kingdom, and the United States in 2020-22.
main outcome measuresNumber and type of claims made for each product and ingredient. References cited were reviewed and risk of bias was assessed for registered clinical trials using the Cochrane risk of bias tool, and for systematic reviews using the Risk Of Bias in Systematic reviews tool.
results757 infant formula products were identified, each with a median of two claims (range from 1 (Australia) to 4 (US)), and 31 types of claims across all products. Of 608 products with ≥1 claims, the most common claim types were "helps/supports development of brain and/or eyes and/or nervous system" (323 (53%) products, 13 ingredients), "strengthens/supports a healthy immune system" (239 (39%) products, 12 ingredients), and "helps/supports growth and development" (224 (37%) products, 20 ingredients). 41 groups of ingredients were associated with ≥1claims, but many claims were made without reference to a specific ingredient (307 (50%) products). The most common groups of ingredients cited in claims were long chain polyunsaturated fatty acids (278 (46%) products, 9 different claims); prebiotics, probiotics, or synbiotics (225 (37%) products, 19 claims); and hydrolysed protein (120 (20%) products, 9 claims). 161/608 (26%) products with ≥1 claims provided a scientific reference to support the claim-266 unique references were cited for 24 different claim types for 161 products. The reference types most frequently cited were clinical trials (50%, 134/266) and reviews (20%, 52/266). 28% (38/134) of referenced clinical trials were registered, 14% (19/134) prospectively. 58 claims referred to 32 registered clinical trials, of which 51 claims (27 trials) related to a randomised comparison. 46 of 51 claims (90%) referenced registered clinical trial outcomes at high risk of bias, and all cited systematic reviews and pooled analyses, carried a high risk of bias.
conclusionsMost infant formula products had at least one health and nutrition claim. Multiple ingredients were claimed to achieve similar health or nutrition effects, multiple claims were made for the same ingredient type, most products did not provide scientific references to support claims, and referenced claims were not supported by robust clinical trial evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.